Sulfotanshinone ⅡA Sodium Ameliorates Lipopolysaccharide-Peritoneal Dialysis Solution-Elicited Human Peritoneal Mesothelial Cells Injury

OBJECTIVE To study the effect and mechanism of sulfotanshinone ⅡA sodium (STS) in human peritoneal mesothelial cells (HPMCs) injury and peritoneal fibrosis caused by lipopolysaccharide-peritoneal dialysis solution (LPS-PDS). METHODS HPMCs was primary cultured from patients undergoing peritoneal surgery. The cells were incubated with LPS-PDS to mimic the peritoneal dialysis conditions in vitro. After treatment of cells with STS， cellular viability was tested and mRNA were collected and subjected to RT-PCR to evaluated the level of TGF-β1， TIMP-1 and MMP-9. RESULTS Incubation HPMCs with LPS-PDS elicited cell injury. STS attenuated LPS-PDS-induced cell injury by improvement of cellular viability. Furthermore， STS inhibited HPMCs fibrosis as evidenced by suppression of TGF-β1 and TIMP1 induced by LPS-PDS and increasing MMP-9 mRNA level. CONCLUSION STS protects HPMCs against LPS-PDS-induced cell injury. Moreover， STS retards HPMCs fibrosis by decreasing TGF-β1 and TIMP1 mRNA level and increasing MMP-9 mRNA.